



January 26, 2012

Re: Update Regarding Supply of Cerezyme® (imiglucerase for injection)

Dear U.S. Healthcare Provider,

We are pleased to inform you that starting February 1, 2012, we expect to provide full supply for patients in the U.S. who are currently receiving Cerezyme. All patients will receive full supply of Cerezyme based on their current prescribed dose and dose frequency on file.

Our current productivity and progress with our manufacturing recovery remains on track and the overall supply outlook for Cerezyme continues to improve. However, since we have minimal inventory, any change to our manufacturing plans can have an immediate impact on our ability to provide product.

Because of present estimated Cerezyme supply levels for 2012, and the availability of alternative therapies, Genzyme currently will not be able to accommodate patients naïve to treatment and/or patients switching therapies.

For any questions, please contact your local Genzyme Representative, or Case Manager at 1-800-745-4447, Option 3, or Genzyme Medical Information at 1-800-745-4447, Option 2.

Sincerely,

A handwritten signature in black ink, appearing to read "D. Gruskin".

Daniel Gruskin, MD,
Head US Medical Affairs

A handwritten signature in black ink, appearing to read "Stephanie S. Okey".

Stephanie Okey, M.S. PGH
Vice President & General Manager U.S. Genetics